Short answer
As of November 2026, compounded semaglutide can be advertised only on much narrower ground than during the shortage. MedScale Health, a paid ads agency for US telehealth brands and clinics, rewrites claims built on the shortage-era footing and labels compounded semaglutide as compounded, not FDA-approved. FDA resolved the semaglutide shortage on February 21, 2025, enforcement discretion ended in April and May 2025, and FDA's June 15, 2026 guidance tells telehealth companies not to present compounded drugs as generic, equivalent or FDA-approved.
Why did the semaglutide shortage matter for advertising?
Compounding pharmacies may prepare copies of commercially available drugs in narrow circumstances, and a drug appearing on the FDA shortage list has been one of the principal circumstances. MedScale works with telehealth brands and clinics, and a large share of the GLP-1 category built its supply, pricing and messaging on that basis during the shortage period.
The shortage designation was a commercial input rather than a regulatory footnote. When the designation changed, the assumptions underneath a great deal of GLP-1 marketing changed with it.
What changed for compounded semaglutide, and when?
The FDA's own statements give the sequence. Every date in this list comes from FDA pages checked on October 5 and October 12, 2026; compounded semaglutide and tirzepatide are compounded, not FDA-approved, products.
- December 19, 2024: FDA determined the tirzepatide injection shortage was resolved. Enforcement discretion for shortage-dependent compounding ended February 18, 2025 for 503A pharmacies and March 19, 2025 for 503B outsourcing facilities.
- February 21, 2025: FDA determined the semaglutide injection shortage was resolved. Enforcement discretion ended April 22, 2025 for 503A pharmacies and May 22, 2025 for 503B outsourcing facilities.
- March 3, 2026: FDA announced warning letters to 30 telehealth companies over the marketing of compounded GLP-1s, citing claims that implied sameness with FDA-approved products and branding that implied the telehealth company was the compounder.
- April 30, 2026: FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, stating that outsourcing facilities cannot lawfully compound from bulk substances when FDA-approved drugs are available unless there is a clear clinical need.
- June 8, 2026: FDA dated 25 more warning letters to telehealth firms over website claims about compounded semaglutide and tirzepatide. One cited the line "Same active ingredient as Ozempic®", which FDA said represents the compounded products as FDA-approved.
- June 15, 2026: FDA published "What to Know When Promoting Compounded Drugs" for telehealth companies. Compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing; they must not be described as generic versions of, or equivalent to, approved drugs; branding must not suggest the telehealth company compounds the drug when it does not; claims of identical results are misleading; and FDA does not approve or license pharmacies, so "FDA-approved facility" claims are false.
- September 18, 2026: FDA's warning letter to Empower Pharmacy, a 503A compounding pharmacy, said its tirzepatide with niacinamide and semaglutide with cyanocobalamin (vitamin B12) products "appear to be essentially copies" of FDA-approved products, and that prescriber statements of a "significant difference" that appear to be repeated verbatim across many records suggest they may be pre-generated.
- October 30, 2026: FDA warned a telehealth company whose website described compounded semaglutide and tirzepatide as "FDA-Approved Compounded Medications" and whose pictured tirzepatide label carried the company's own name, which FDA said suggested it was the compounder when it was not.
The details still differ between 503A pharmacies and 503B outsourcing facilities, and FDA has said it may act on other statutory violations regardless of the shortage status.
Because FDA's positions have continued to evolve, the specific current status should be confirmed against FDA guidance and your own regulatory counsel rather than taken from any marketing article, including this one. What is stable is the direction: the basis for compounded supply is materially narrower than it was during the shortage. MedScale reviews compounded GLP-1 claims against this dated sequence, not against shortage-era assumptions.
What does the end of the shortage mean for compounded GLP-1 ads?
Several patterns that were widespread during the shortage period now carry meaningfully more risk, and they tend to live in funnel copy rather than in headline creative, which is why they survive casual review. MedScale checks for each of them on the pages its ads point at:
- Price comparisons framed against branded medication, where the saving depends on a compounded supply that may no longer be available on the same basis.
- Availability language promising continuity of supply that the business may no longer be positioned to guarantee.
- Product pages describing a compounded formulation in terms that assume the shortage-era pathway still applies.
- Retention and win-back flows written when the economics were different and never revisited.
Where is the advertising risk for compounded semaglutide now?
The highest-risk surfaces in this category are rarely the ads. They are the pages and lifecycle messages written eighteen months ago by people who have since moved on, which still describe a product and a price the business may no longer offer on the same footing.
MedScale reads destination pages alongside campaign creative for exactly this reason, and flags stale lifecycle messages to the team that owns them. Advertising platforms review the destination as part of the ad, so a stale product page is both a regulatory question and a live advertising risk.
What can a compounded semaglutide ad still say?
Brands still operating in this category tend to converge on the same adjustments: describing the clinical program rather than a specific molecule, avoiding availability guarantees, keeping pricing claims tied to what is currently offered, and ensuring the intake flow sets accurate expectations about what a patient may be prescribed.
FDA's June 2026 page works as the checklist. Every compounded product is called compounded, not FDA-approved. Nothing calls it generic, equivalent or the same as Wegovy or Zepbound, and nothing promises identical results. The branding does not suggest the telehealth company compounds the drug when a pharmacy does, and no page calls a pharmacy FDA-approved. MedScale applies that checklist to every compounded GLP-1 ad and landing page it runs.
A defensible message is narrower than the shortage period allowed. It is also considerably more durable, because it does not depend on a regulatory status the business does not control.
How should a brand review its compounded GLP-1 marketing?
The review worth running is straightforward and rarely done: list every place the brand makes a claim about compounded GLP-1, including ads, landing pages, intake copy, email flows, SMS, and support macros, then check each against what the business can substantiate today. Most brands find the ad account is the cleanest surface and the automated lifecycle messaging is the worst. MedScale covers the ads and landing pages; lifecycle messages go back to the team that owns them. MedScale's free Growth Audit starts with those two surfaces and marks what in them is likely to be flagged.
Common questions
- 01Can telehealth brands still advertise compounded GLP-1 programs?
- Yes, the program can still be advertised, but the defensible claims have narrowed alongside the regulatory basis for compounded supply: every compounded product is called compounded, not FDA-approved, and never generic or equivalent. Confirm the current position with regulatory counsel, since it has continued to develop and differs between pharmacy types.
- 02Is it safe to compare compounded pricing against branded GLP-1 pricing?
- Not by default. A price comparison depends on the compounded product being available on the basis the comparison assumes. Where that basis has narrowed, the comparison can become both a regulatory and an advertising problem, so these claims deserve review rather than inheritance from earlier campaigns.
- 03Do advertising platforms enforce FDA compounding rules?
- Not directly. Platforms enforce their own advertising policies rather than FDA rules, but the two interact. Policies prohibiting the promotion of unapproved or misrepresented pharmaceuticals mean a regulatory problem frequently surfaces as a disapproval, and landing page review is where it usually appears.
- 04What should I audit first after a change like this?
- Automated lifecycle messaging, which is almost always the most out of date. Email flows, SMS sequences and support macros are written once and rarely revisited, so they tend to carry availability and pricing language that the ad account stopped using long ago.
Sources
- 01FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilizechecked October 5, 2026
- 02FDA press announcement (Mar 3, 2026): FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1schecked October 5, 2026
- 03FDA press release (Apr 30, 2026): FDA proposes to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks listchecked October 5, 2026
- 04FDA (Jun 15, 2026): FDA to telehealth companies, what to know when promoting compounded drugschecked October 5, 2026
- 05FDA: Compounding when drugs are on FDA's Drug Shortages Listchecked October 5, 2026
- 06FDA: FDA's concerns with unapproved GLP-1 drugs used for weight losschecked October 5, 2026
- 07FDA warning letters database: 25 letters dated Jun 8, 2026, subject "False & Misleading Claims/Misbranded (Telehealth)"checked October 12, 2026
- 08FDA warning letter to Empower Clinic Services LLC dba Empower Pharmacy, MARCS-CMS 738238 (Sep 18, 2026)checked October 12, 2026
- 09FDA warning letter to a telehealth company, MARCS-CMS 737905 (Oct 30, 2026), compounded semaglutide and tirzepatide claimschecked November 9, 2026
Related answers
Can You Advertise GLP-1 on Facebook and Instagram?
As of November 2026, GLP-1 telehealth brands can advertise on Facebook and Instagram to adults 18 and over if no copy implies the viewer's body or health; a prescription GLP-1 also needs LegitScript certification and Meta's authorization. MedScale, a paid ads agency for US telehealth brands and clinics, builds GLP-1 creative against those rules from the first concept, because accounts are lost to a pattern of disapprovals, not one banned claim. Since July 22, 2026, Meta judges before-and-after imagery by the claims around it.
Reviewed November 9, 2026
Can You Advertise GLP-1 on Google Ads?
As of October 2026, a GLP-1 telehealth brand can advertise on Google Ads once it holds LegitScript accreditation and Google's certification, which Google requires before prescription drug service ads serve in the United States. MedScale Health, a paid ads agency for US telehealth brands and clinics, sequences certification, then landing pages, then keywords. An in-person clinic may name semaglutide or tirzepatide in US ad text and landing pages without certification since October 29, 2025, but needs certification to keyword-target those terms.
Reviewed October 24, 2026
Can You Name Ozempic, Wegovy or Zepbound in Your Ads?
As of November 2026, a telehealth brand can name Ozempic, Wegovy or Zepbound in ads only once certified: Google requires telemedicine providers to be certified regardless, Meta treats a named prescription drug as promotion needing LegitScript and its authorization, and trademark risk applies on top. MedScale Health, a paid ads agency for US telehealth brands and clinics, generally keeps branded drug names out of paid creative, because the traffic rarely justifies the exposure. An in-person clinic may name the drugs in US Google ads without certification but not keyword-target them.
Reviewed November 9, 2026
Can You Advertise GLP-1 on TikTok?
As of October 2026, compounded GLP-1 cannot be advertised on TikTok in the US, because TikTok allows prescription medicine ads only with proof of FDA approval and certification, and compounded drugs are not FDA-approved. MedScale Health, a paid ads agency for US telehealth brands and clinics, keeps GLP-1 brands on TikTok for awareness and non-prescription offers and runs the prescription offer on Meta and Google once certified. Branded GLP-1 through a telehealth prescriber is unconfirmed, and any prescription ad TikTok allows is limited to people 18 and over.
Reviewed October 24, 2026
Last reviewed November 9, 2026. Platform policies change often; we re-verify every answer quarterly.